Researchers from the University of Miami Miller School of Medicine outline the potential of intra-arterial stem cell therapy to improve recovery for stroke patients, who often face disability despite major advances in treatment. The therapy works by promoting brain repair, reducing inflammation, and enhancing recovery.
A new study found that alcohol-attributable cancer deaths in the US doubled between 1990 and 2023, with colorectal and breast cancers standing out among adults ages 20 to 54. The study also revealed that alcohol-linked cancer deaths are not limited to older adults or liver cancer.
A study by the University of Miami Miller School of Medicine found that cancer-specific messages paired with AI-generated visuals draw more attention and stronger intentions to cut back on drinking. The study showed that messages named particular cancers performed better than broad warnings about cancer risk.
Sylvester Cancer Center has ranked #1 in Florida and #23 nationwide, thanks to discoveries of a genetic mutation that enables blood cancers to evade BTK inhibitors. Researchers are exploring new therapies and using AI to advance precision medicine.
Researchers redefine neurodegenerative diseases as TDP-43 associated neurodegenerative disease (TAND), which shares biological roots with ALS, FTD, and LATE. This new framework could lead to more efficient drug development and improved clinical trials for rare conditions.
A new study suggests that younger, less genetically matched donors can produce encouraging outcomes for blood cancer patients. Researchers found that carefully selected mismatched donors can produce favorable outcomes, potentially widening access to a potentially lifesaving transplant.
A large international study suggests that age may influence lung cancer biology and could help guide more personalized treatment strategies. Younger adults with non-small cell lung cancer are significantly more likely to have genetic alterations that can be matched with targeted therapies.
The Sylvester Comprehensive Cancer Center has been ranked the No. 1 cancer program in Florida and No. 23 nationally by US News & World Report. The center's multidisciplinary teams provide access to new therapies and innovative clinical trials, making it a destination for patients seeking advanced care.
A new clinical study demonstrates casdatifan's effectiveness in treating advanced kidney cancer with durable tumor responses and a manageable safety profile. The treatment targets HIF-2 biology and biomarker changes, supporting precision medicine approaches.
A three-year research award from Gabrielle’s Angel Foundation will support the study of transcutaneous auricular vagus nerve stimulation (taVNS) to manage chemotherapy-induced peripheral neuropathy symptoms. The goal is to improve quality of life for cancer patients with long-term effects of treatment.
Researchers identified a rare genetic mutation, BTK A428D, that blocks both BTK inhibitors and next-generation BTK degraders. The study provides new insight into how cancers evolve under treatment pressure and may help develop strategies to overcome resistance in patients with chronic lymphocytic leukemia.
Sylvester researchers develop AI-powered fracture prediction models, train as wildland firefighters to reduce cancer risk, and discover new targets for pancreatic cancer treatment. A new tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells.
Researchers have developed a microfluidic platform that recreates the complex ecosystem surrounding pancreatic tumors and observed how cells interact dynamically. The findings reveal a critical mechanism that may explain why many therapies fail and point to new therapeutic strategies.
Researchers identified a critical biological difference in glioblastoma development between male and female laboratory models, pinpointing an immune pathway fueled by GABA in females. Blocking this signal improves outcomes in women, but not men.
Researchers have identified IL1RAP as a key player in the tumor-driven inflammatory network that helps pancreatic cancer resist treatment. Blocking this receptor may help break down tumors and improve response to combination therapy.
The Sylvester Cancer Institute has made significant breakthroughs in multiple myeloma treatment with the immunotherapy drug teclistamab, which extends remission and survival rates. Additionally, research has shed light on glioma evolution after treatment and identified genetic markers for aggressive solitary fibrous tumors.
A new national analysis found that mesothelioma deaths and diagnoses continue to rise in the US, with little improvement in survival rates. The disease disproportionately affects women and several high-risk states tied to shipbuilding, mining, and legacy asbestos exposure.
Researchers found that extreme heat impacts daily life, access to care, and treatment-related decisions among people with cancer. Participants adapted by limiting outdoor activity, but these compromises affected health, independence, and quality of life.
In a landmark international trial, teclistamab outperformed standard treatments in extending survival and remission for patients with relapsed multiple myeloma. Nearly 70% of patients remained disease-free after 18 months, and nearly two-thirds achieved complete remission.
A new study from the University of Miami Miller School of Medicine suggests that machine learning models using patient-reported outcomes and clinical data can forecast unplanned health care use and elevated symptom burden in cancer survivors. The research offers a potential pathway toward more proactive, personalized survivorship care.
Researchers developed an AI-based tool to predict patient outcomes and tailor treatment strategies for newly diagnosed multiple myeloma patients. The analysis revealed that low CD16 levels were associated with shorter time to next treatment, improving disease control and quality of life.
Researchers identified specific gene fusion patterns linked to more aggressive disease behavior and increased risk of metastasis in solitary fibrous tumors. The study suggests that these molecular differences could serve as potential biomarkers for predicting patient outcomes and guiding treatment decisions.
A phase I clinical trial is testing whether a tumor-targeting virus can help immunotherapy work more effectively against aggressive neuroendocrine tumors. The study uses a combination of immunotherapy medications and an oncolytic virus delivered directly into the tumors, aiming to improve treatment outcomes.
A phase 2 clinical trial found that 65% of patients receiving avatrombopag met key treatment goals, compared to 17% of those receiving placebo treatment. The oral medication has been shown to be effective in maintaining platelet counts needed to continue chemotherapy as scheduled.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
A new study found that targeted maternal screening can prevent adult T-cell leukemia/lymphoma, a rare and aggressive cancer caused by human T-cell leukemia virus type 1. The research identified high disease rates among non-Hispanic Caribbean-born US residents, particularly in Florida and New York.
A large U.S. study found that adults who never married have substantially higher rates of developing cancer compared to those who are or have been married. The association is strongest for cancers related to infection, smoking, and alcohol use, with women facing a significantly higher risk than men.
Researchers have developed a new single-cell technology called CIPHER-seq that captures the timing of cytokine activity with greater accuracy. This allows for a clearer view of immune cell behavior and strengthens the foundation for understanding cancer, inflammation, and treatment resistance.
A new study found that metformin raises levels of N-lactoyl-phenylalanine, a molecule tied to energy balance and weight control, in men with prostate cancer. This finding suggests metformin could help counter metabolic strain caused by hormone therapy, which often limits physical activity.
A new national study highlights the genetic changes that link exposure to Agent Orange to myelodysplastic syndromes, a group of bone marrow cancers that can progress to acute leukemia. The research found that exposed veterans were diagnosed at a younger age and had a higher rate of disease progression compared to unexposed patients.
A phase 3 clinical trial found romiplostim significantly reduced chemotherapy dose delays and improved platelet counts in patients with gastrointestinal cancers who developed persistent low platelet counts during treatment. The therapy enables patients to maintain chemotherapy intensity, potentially preserving the integrity of cancer c...
The Sylvester Cancer Tip Sheet for March 2026 highlights the importance of genetic testing for cancer risk assessment. Researchers have made significant progress in developing new treatments, including mRNA-based immunotherapy for colorectal and pancreatic cancers. Additionally, the Dolphins Cancer Challenge has surpassed $100 million ...
Researchers found that tumors with androgen receptor alterations experienced poorer outcomes, shorter overall survival, and earlier need for subsequent therapy. Serial liquid biopsies revealed real-time molecular changes linked to treatment pressure.
A new study shows that exercise during chemotherapy measurably improves quality of life for women with breast cancer, with benefits consistent across physical, emotional and mental health domains. The findings support existing clinical guidelines and provide clarity on the effectiveness of exercise interventions during treatment.
Researchers at Sylvester Cancer Institute have identified a potential workaround for chemotherapy resistance by blocking a key protein. The study aims to teach lymphoma patients practical tools to manage stress and improve their daily quality of life through the SMART 3RP Lymphoma study. Meanwhile, the institute is expanding cancer dis...
A new study suggests blocking key protein p300 can create novel form of cellular stress in cancer cells, re-sensitizing chemo-resistant tumors. Cells produce proteins even with damaged DNA, leading to toxic buildup and stress inside the cell's internal quality-control system.
New studies from Sylvester reveal that 40% of cancers are preventable and that lifestyle interventions can play a crucial role in cancer treatment. Researchers also discovered PFAS on firefighter gear, which may limit exposure to hazardous chemicals linked to cancer.
A recent analysis of 692 clinical trials found that industry-sponsored trials were nearly three times more likely to fail compared to government-funded studies. Trials with higher participant numbers and broader eligibility criteria were also more likely to complete successfully.
A new study suggests that durvalumab may offer a promising treatment option for limited-stage small cell lung cancer patients, extending overall and progression-free survival. However, the therapy's high cost poses significant challenges to sustainability and access in the real-world setting.
A new study has validated a non-destructive method to detect 'forever chemicals' on protective equipment, reducing the risk of cancer to firefighters. Researchers found PFAS in every set of firefighter gear examined, including breathing masks, with concentrations reaching hundreds of nanograms per gram.
CORAL accurately predicts genetic subtypes and patient outcomes in multiple myeloma without costly genomic tests. The technology could be applied to other cancers, opening the door to personalized, faster and widely accessible cancer care.
A virtual diet and exercise program has been shown to reduce treatment side effects and increase treatment retention, according to a Sylvester study presented at ASH 2025. Lifestyle interventions can also help patients with blood cancers such as MDS and large B-cell lymphoma receive more effective and less toxic treatments.
A new clinical trial suggests that combining bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may significantly enhance one-year progression-free survival for people with aggressive lymphoma. The study found that 90% of patients were in complete remission at day 90, and about 80% remained in remission at one y...
A new national study reveals a strong link between Agent Orange exposure and the risk of developing myelodysplastic syndrome, with exposed veterans diagnosed at younger ages and experiencing more aggressive disease. The study found that those with MDS were nearly twice as likely to see their disease progress within two years after diag...
A new study finds that most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than intensive chemotherapy. The R-CHOP regimen has shown strong four-year survival rates for THRLBCL patients without significant side effects.
A new study presented at ASH 2025 suggests that a virtual program focusing on diet and exercise can help reduce the severity of side effects associated with lymphoma treatment. The program, LIFE-L, showed significant improvements in symptoms such as anxiety, depression, pain, fatigue, and constipation among participants.
A clinical trial found that linvoseltamab, a bispecific antibody, eliminated 90% of tumor cells in patients with residual disease. The treatment allows patients to bypass high-dose chemotherapy and bone marrow transplants, potentially improving long-term outcomes.
A new study presented at the 2025 American Society of Hematology meeting revealed that subtle disruptions in genome architecture can predispose individuals to lymphoma. The research found that damaged 3D genome architecture can silence key tumor suppressor genes, creating fertile ground for malignancy.
Researchers have found that patients with blood cancers can safely receive stem cell transplants from mismatched, unrelated donors using a protective regimen. The study's findings could make transplants accessible to nearly all patients with blood cancers, regardless of ancestry.
The updated 2025 American Society of Hematology guidelines recommend that most older adults with acute myeloid leukemia (AML) receive treatment, including gentler chemotherapy regimens and targeted therapies. The guidelines aim to provide more personalized and effective care for this patient population.